Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

Yujuan Yue, Zhongde Wang, Kristina Abel, Jinliang Li, Lisa Strelow, Angelo Mandarino, Meghan K. Eberhardt, Kimberli A. Schmidt, Don J. Diamond, Peter A Barry

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalMedical Microbiology and Immunology
Volume197
Issue number2
DOIs
StatePublished - Jun 2008

Keywords

  • Cytomegalovirus vaccine
  • Modified vaccinia Ankara virus
  • Rhesus macaques

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology

Fingerprint Dive into the research topics of 'Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques'. Together they form a unique fingerprint.

  • Cite this

    Yue, Y., Wang, Z., Abel, K., Li, J., Strelow, L., Mandarino, A., Eberhardt, M. K., Schmidt, K. A., Diamond, D. J., & Barry, P. A. (2008). Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Medical Microbiology and Immunology, 197(2), 117-123. https://doi.org/10.1007/s00430-008-0074-5